Pancreatic Cancer Research

ResearcherMemorial Sloan Kettering Cancer CenterActive in the last 2 years

Olca Baştürk

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-2747-1366; OpenAlex author ID A5085620004, A5127314788, A5158588069; NIH RePORTER profile ID 11613502. Sources: OpenAlex.

Their work

Papers
34 (first author 1, last author 0)
Trials
0
Grants
1
Labs led
0
Collaborators
203
Papers, trials and grants by year

2015: 2 papers · 2016: 1 paper · 2017: 3 papers · 2018: 2 papers · 2019: 2 papers · 2020: 3 papers · 2021: 4 papers · 2022: 2 papers · 2023: 1 paper · 2024: 3 papers · 2025: 2 papers · 2026: 9 papers, 1 grant

Papers 34

  1. "Simple Mucinous Cysts" associated with pancreatic ductal adenocarcinoma: clinicopathologic and radiologic characterization of an enigmatic cyst and additional… Co-author DOI 10.1007/s00428-026-04705-w↗
  2. Pembrolizumab and olaparib in homologous-recombination-deficient metastatic pancreatic cancer: the phase 2 POLAR trial. Co-author DOI 10.1038/s41591-026-04299-5↗
  3. NRG1 fusion-positive solid tumors: clinical detection, genomic landscape, and real-world data in pancreatic cancer. Co-author DOI 10.1093/jnci/djaf361↗
  4. "Horses out of the barn": pancreatic ductal adenocarcinoma frequently extends beyond the grossly visible tumour, requiring microscopic rectification for accura… Co-author DOI 10.1111/his.70099↗
  5. Brain metastasis from KRAS wild-type pancreatic cancer and organoid correlates: a case report. Co-author DOI 10.21037/jgo-2025-aw-818↗
  6. Pancreatic Adenocarcinoma, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology. Co-author DOI 10.6004/jnccn.2026.0046↗
  7. POLQ-driven repair scars shape the immunogenic landscape of homologous recombination-deficient pancreatic cancer Co-author DOI 10.64898/2026.03.15.711961↗
  8. Invasion status stratifies the composition of the human pancreatic cancer perineural niche Co-author DOI 10.64898/2026.08.05.743048↗
  9. Neoantigen-reactive CD8 + T cell engagement marks exceptional survivors of pancreatic cancer Co-author DOI 10.64898/2026.09.17.752426↗
  10. RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer. Co-author DOI 10.1038/s41586-024-08508-4↗
  11. Clinicogenomic landscape of pancreatic adenocarcinoma identifies KRAS mutant dosage as prognostic of overall survival. Co-author DOI 10.1038/s41591-024-03362-3↗
  12. Multi-parametric atlas of the pre-metastatic liver for prediction of metastatic outcome in early-stage pancreatic cancer. Co-author DOI 10.1038/s41591-024-03075-7↗
  13. Artificial Intelligence-based Segmentation of Residual Pancreatic Cancer in Resection Specimens Following Neoadjuvant Treatment (ISGPP-2): International Improv… Co-author DOI 10.1097/pas.0000000000002270↗
  14. A Classical Epithelial State Drives Acute Resistance to KRAS Inhibition in Pancreatic Cancer. Co-author DOI 10.1158/2159-8290.cd-24-0740↗
  15. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Co-author DOI 10.1038/s41586-023-06063-y↗
  16. Histopathological tumour response scoring in resected pancreatic cancer following neoadjuvant therapy: international interobserver study (ISGPP-1). Co-author DOI 10.1093/bjs/znac350↗
  17. Pathologic Examination of Pancreatic Specimens Resected for Treated Pancreatic Ductal Adenocarcinoma: Recommendations From the Pancreatobiliary Pathology Socie… Co-author DOI 10.1097/pas.0000000000001853↗
  18. Amsterdam International Consensus Meeting: tumor response scoring in the pathology assessment of resected pancreatic cancer after neoadjuvant therapy. Co-author DOI 10.1038/s41379-020-00683-9↗
  19. Towards a More Standardized Approach to Pathologic Reporting of Pancreatoduodenectomy Specimens for Pancreatic Ductal Adenocarcinoma: Cross-continental and Cro… Co-author DOI 10.1097/pas.0000000000001723↗
  20. Pancreatic cancer stem cells may define tumor stroma characteristics and recurrence patterns in pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12885-021-08123-w↗
  21. Expression of Calretinin, Marker of Mesothelial Differentiation, in Pancreatic Ductal Adenocarcinoma: A Potential Diagnostic Pitfall. First author DOI 10.5146/tjpath.2020.01519↗
  22. Genetic and clinical correlates of entosis in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41379-020-0549-5↗
  23. A unifying paradigm for transcriptional heterogeneity and squamous features in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s43018-019-0010-1↗
  24. Induction and characterization of pancreatic cancer in a transgenic pig model. Co-author DOI 10.1371/journal.pone.0239391↗
  25. CT radiomics associations with genotype and stromal content in pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00261-019-02112-1↗
  26. The Genetic Basis of Transcriptional and Spatial Heterogeneity of Squamous Features in Pancreatic Ductal Adenocarcinoma Co-author DOI 10.1101/548354↗
  27. Brain Metastases in Pancreatic Ductal Adenocarcinoma: Assessment of Molecular Genotype-Phenotype Features-An Entity With an Increasing Incidence? Co-author DOI 10.1016/j.clcc.2018.01.009↗
  28. Extracellular matrix proteins and carcinoembryonic antigen-related cell adhesion molecules characterize pancreatic duct fluid exosomes in patients with pancrea… Co-author DOI 10.1016/j.hpb.2017.12.010↗
  29. Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer. Co-author DOI 10.1038/nature24462↗
  30. Multi-institutional Validation Study of the American Joint Commission on Cancer (8th Edition) Changes for T and N Staging in Patients With Pancreatic Adenocarc… Co-author DOI 10.1097/sla.0000000000001763↗
  31. Real-Time Genomic Profiling of Pancreatic Ductal Adenocarcinoma: Potential Actionability and Correlation with Clinical Phenotype. Co-author DOI 10.1158/1078-0432.ccr-17-0899↗
  32. Pancreatic Ductal Adenocarcinoma is Spread to the Peripancreatic Soft Tissue in the Majority of Resected Cases, Rendering the AJCC T-Stage Protocol (7th Editio… Co-author DOI 10.1245/s10434-016-5093-7↗
  33. Organoid models of human and mouse ductal pancreatic cancer. Co-author DOI 10.1016/j.cell.2014.12.021↗
  34. Substaging of Lymph Node Status in Resected Pancreatic Ductal Adenocarcinoma Has Strong Prognostic Correlations: Proposal for a Revised N Classification for TN… Co-author DOI 10.1245/s10434-015-4861-0↗

Grants 1

  1. Biostatistics Core P50CA257881↗

Closest collaborators

The 25 strongest of 203 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Eileen Mary O'Reilly · 10 shared papers, 1 shared grant, 2017–2026 · strength 2.04
  2. Christine A. Iacobuzio–Donahue · 11 shared papers, 1 shared grant, 2015–2026 · strength 1.79
  3. Vinod P. Balachandran · 6 shared papers, 1 shared grant, 2017–2026 · strength 1.36
  4. Marinela Capanu · 4 shared papers, 1 shared grant, 2021–2026 · strength 1.35
  5. Volkan N. Adsay · 9 shared papers, 2015–2026 · strength 1.19
  6. Alice Chia-Chi Wei · 3 shared papers, 1 shared grant, 2025–2026 · strength 1.18
  7. Kenneth H. Yu · 7 shared papers, 2015–2026 · strength 0.96
  8. Nuray Tezcan · 4 shared papers, 2026 · strength 0.88
  9. Fiyinfolu O. Balogun · 4 shared papers, 2025–2026 · strength 0.81
  10. Gökçe Aşkan · 7 shared papers, 2017–2021 · strength 0.74
  11. Wungki Park · 4 shared papers, 2025–2026 · strength 0.70
  12. Michelle Dian Reid · 5 shared papers, 2015–2026 · strength 0.70
  13. Jason Stuart Lewis · 1 shared grant, 2026 · strength 0.67
  14. Anna M. Varghese · 5 shared papers, 2017–2026 · strength 0.66
  15. Burcu Saka · 4 shared papers, 2015–2026 · strength 0.57
  16. Pelin Bağcı · 4 shared papers, 2015–2026 · strength 0.57
  17. Benjamin D. Greenbaum · 4 shared papers, 2017–2026 · strength 0.57
  18. Ralph H. Hruban MD · 7 shared papers, 2015–2022 · strength 0.55
  19. Alyssa M. Krasinskas · 5 shared papers, 2015–2026 · strength 0.54
  20. Kevin C. Soares · 3 shared papers, 2025–2026 · strength 0.52
  21. William R. Jarnagin · 5 shared papers, 2017–2025 · strength 0.51
  22. Huamin Wang · 4 shared papers, 2021–2024 · strength 0.46
  23. Iréne Esposito · 4 shared papers, 2021–2024 · strength 0.46
  24. Mara H. Sherman · 2 shared papers, 2026 · strength 0.45
  25. Akimasa Hayashi · 4 shared papers, 2019–2026 · strength 0.43

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.